Summary
Immunotherapies, which harness the immune system to fight disease, are revolutionising the treatment of many cancers and inflammatory diseases. However, while these innovative treatments prove life-saving for some patients, others do not respond to immunotherapies at all, and others experience serious side effects. The Immune-Image project aims to pioneer the use of non-invasive imaging technologies to track the activity of immune cells in the body. Ultimately, the project will make it easier to predict how patients will respond to treatment and monitor their progress during treatment.
To do this, the project will develop tracers capable of highlighting specific immune cells in a range of imaging types, including magnetic resonance imaging (MRI), positron emission tomography (PET), optical imaging (OI) and computed tomography (CT). They will also analyse biopsies and blood samples to build up complete immunological profiles of patients and to correlate imaging findings with pathology; this information will contribute to the development of personalised immunotherapies.
Achievements & News
March 2025
New tools developed by the Immune-Image project can indicate the presence of cells that inhibit immunotherapy.
July 2024
Drugs for IBD work in some patients, but not others. The Immune-Image project used imaging techniques to illuminate how the...
Participants
Show participants on mapEFPIA companies
- Bayer Aktiengesellschaft, Leverkusen, Germany
- F. Hoffmann-La Roche AG, Basel, Switzerland
- Imaginab, Inc, Inglewood Ca, United States
- Janssen Pharmaceutica Nv, Beerse, Belgium
- Novartis Pharma AG, Basel, Switzerland
- Pfizer Limited, Sandwich, United Kingdom
- Takeda Pharmaceuticals International AG, Glattpark, Switzerland
Universities, research organisations, public bodies, non-profit groups
- Academisch Ziekenhuis Groningen, Groningen, Netherlands
- Commissariat A L Energie Atomique Et Aux Energies Alternatives, Paris 15, France
- Eberhard Karls Universitaet Tuebingen, Tuebingen, Germany
- Fundacio Hospital Universitari Vall D'Hebron - Institut De Recerca, Barcelona, Spain
- Fundacio Privada Institut D'Investigacio Oncologica De Vall-Hebron (Vhio), Barcelona, Spain
- Stichting Amsterdam Umc, Amsterdam, Netherlands
- Universitaet Muenster, Muenster, Germany
- University of Cambridge, Cambridge, United Kingdom
- Vib Vzw, Zwijnaarde - Gent, Belgium
- Vrije Universiteit Brussel, Bruxelles / Brussel, Belgium
Small and medium-sized enterprises (SMEs) and mid-sized companies (<€500 m turnover)
- Antaros Medical AB, Molndal, Sweden
- Lawrencium Legal BV, Amsterdam, Netherlands
- PNO Life Sciences & Health B.V., Rijswijk, Netherlands
- Stichting Lygature, Utrecht, Netherlands
Third parties
- Cloudselling BV, Rijswijk, Netherlands
| Participants | |
|---|---|
| Name | EU funding in € |
| Academisch Ziekenhuis Groningen | 2 174 208 |
| Antaros Medical AB | 250 000 |
| Commissariat A L Energie Atomique Et Aux Energies Alternatives | 510 000 |
| Eberhard Karls Universitaet Tuebingen | 1 103 496 |
| European Cancer Patient Coalition (left the project) | 80 000 |
| Fundacio Hospital Universitari Vall D'Hebron - Institut De Recerca | 514 560 |
| Fundacio Privada Institut D'Investigacio Oncologica De Vall-Hebron (Vhio) | 433 310 |
| Lawrencium Legal BV | 400 000 |
| PNO Life Sciences & Health B.V. | 290 000 |
| Stichting Amsterdam Umc | 3 361 722 |
| Stichting Lygature | 450 000 |
| Universitaet Muenster | 1 930 000 |
| University of Cambridge | 1 041 875 |
| Vib Vzw | 885 000 |
| Vrije Universiteit Brussel | 1 445 829 |
| Third parties | |
| Name | Funding in € |
| Cloudselling BV | 130 000 |
| Total Cost | 15 000 000 |
Albert D Windhorst
Stichting Amsterdam Umc